sodium iopodate Report issue

Small molecule Approved FDA Priority Review FDA
ChEMBL Drug Central Drugs@FDA PubChem

Active Ingredient History

NOW
  • Now
Iopanoic acid and ipodate salts have been used for oral cholangiography to visualize the biliary ducts. Ipodate salts have been used for the long-term treatment of Graves' disease and in hyperthyroidism. Ipodate reduced levels of T3 and T4 in the patients. Ipodate also inhibits the conversion of T4 to T3. It is not considered a first-line approach. Ipodate sodium lacks FDA approval for these uses. During investigation of mechanism of action was discovered, that binding of sodium ipodate with nuclear T3 receptors was not a prominent mechanism via which the drug attenuates T3 effects in vivo. Sodium ipodate could enhance T3 effects at the cellular level and that enhancement could not be reflected by routinely monitored serum TSH.   NCATS

Chemistry

  • SMILES: CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I
  • InChIKey: YQNFBOJPTAXAKV-UHFFFAOYSA-N
  • Mol. Mass: 597.9572
  • ALogP: 3.74
  • ChEMBL Molecule:
    ipodate sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

bilivist | ipodate sodium | oragrafin sodium | sodium iopodate | sodium ipodate

Organizations (2)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Graves Disease (approved 1962)

Hyperthyroidism (approved 1962)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue